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ABSTRACT
Regarding the urgency of therapeutic measures for coronavirus disease 2019 (COVID-19) pandemic,
the use of available drugs with FDA approval is preferred because of the less time and cost required
for their development. In silico drug repurposing is an accurate way to speed up the screening of the
existing FDA-approved drugs to find a therapeutic option for COVID-19. The similarity in SARS-CoV-2
and HIV-1 fusion mechanism to host cells can be a key point for Inhibit SARS-CoV-2 entry into host
cells by HIV fusion inhibitors. Accordingly, in this study, an HIV-1 fusion inhibitor called Enfuvirtide
(Enf) was selected. The affinity and essential residues involving in the Enf binding to the S2 protein of
SARS-CoV-2, HIV-1 gp41 protein and angiotensin-converting enzyme 2 (ACE-2) as a negative control,
was evaluated using molecular docking. Eventually, Enf-S2 and Enf-gp41 protein complexes were simu-
lated by molecular dynamics (MD) in terms of binding affinity and stability. Based on the most import-
ant criteria such as docking score, cluster size, energy and dissociation constant, the strongest
interaction was observed between Enf with the S2 protein. In addition, MD results confirmed that Enf-
S2 protein interaction was remarkably stable and caused the S2 protein residues to undergo the few-
est fluctuations. In conclusion, it can be stated that Enf can act as a strong SARS-CoV-2 fusion inhibitor
and demonstrates the potential to enter the clinical trial phase of COVID-19.
Abbreviations: ACE-2: angiotensin-converting enzyme 2; Enf: Enfuvirtide; FDA: Food and Drug
Administration; HIV: human immunodeficiency virus; MD: molecular dynamics; RBD: receptor bind-
ing domain
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1. Introduction
The outbreak of coronavirus disease 2019 (COVID-19) which
is caused by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) was started from the Wuhan (China) (Arshad
Ali et al., 2020; Li & Liu, 2020). Afterward, the terrible disease
rapidly spread all over the world so that by December 25,
2020, more than 79.4 million people have been confirmed to
be infected with SARS-CoV-2 and more than 1,740,000
deaths due to COVID-19 have been recorded worldwide
(Chen, 2020; Li & Liu, 2020). On 11th March 2020, WHO
declared COVID-19 as a pandemic due to its high contagion
and mortality rate (Cucinotta & Vanelli, 2020). No approved
vaccine or effective drug has been reported for COVID-19 yet
(Bhagavathula et al., 2020). Regarding the urgency of thera-
peutic measures for COVID-19, the use of available drugs
with FDA approval is preferred because they need to the less
time and cost for the evaluation and development (Durojaiye
et al., 2020). Computer-aided drug repurposing represents an
accurate strategy to speed up the screening of existing drugs
with FDA approval to find the suitable treatment options for
COVID-19 (Ciliberto & Cardone, 2020; Wang, 2020). Similar to
SARS-CoV, SARS-CoV-2 is an enveloped positive-strand RNA
virus (Romano et al., 2020). The cell surface receptor of both
viruses is angiotensin-converting enzyme 2 (ACE-2), however
the apparent affinity of SARS-CoV-2 to ACE-2 is 10 to 20
times higher than that of SARS-COV (Fani et al., 2020). The
genetics alignments showed that the SARS-CoV-2 genome
had 88–89% similarity to two other bats-derived SARS-like
coronaviruses namely bat-SL-CoVZC45 and bat-SL-CoVXC21.
Also, 82 and 50% of the SARS-CoV-2 genome is similar to
SARS-CoV and MERS-CoV genomes, respectively (Lai et al.,
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